GLP-1 medications
GLP-1 is a hormone your gut releases after you eat — it tells your brain you're full and helps your body manage blood sugar. GLP-1 medications (semaglutide, tirzepatide, and newer molecules) copy that signal, which is why they're so widely studied for weight management and metabolic health.
The articles below explain how these medications work, what the research actually shows, and what side effects and dosing schedules look like in practice. Promise offers compounded GLP-1 medications by prescription only: a licensed provider reviews every request, and not everyone qualifies.
250 articles on this topic
-

Generic Semaglutide Exists—Just Not in the U.S.
Canada now has authorized semaglutide generics. The U.S. has only a tentative approval, while compounded semaglutide is another category altogether.
-

Orforglipron Is Approved: What Foundayo Changes
Orforglipron is now sold as Foundayo, a once-daily GLP-1 pill for weight management. It removes the fasting rules of oral semaglutide, but it does not replace every reason someone may choose an injection.
-

Retatrutide Early Access Is Real—and Very Limited
Retatrutide early access now exists through a narrow, doctor-led program. It is not a public prescription route, a sale, or an approval.
-

Tirzepatide Before and After: An Honest Timeline
Tirzepatide before and after photos can't tell you what caused a change. The trials give a more useful timeline: early appetite shifts, months of gradual change, and a later plateau that varies widely.
-

Semaglutide and Kidney Disease: The Full Picture
In the largest trial on the question, serious kidney events were 24% less common on semaglutide than on placebo. The other half of the story is dehydration — and the two keep getting confused.
-

Tirzepatide and Blood Pressure: Does It Lower It?
Yes—blood pressure often falls during tirzepatide treatment, mostly alongside weight loss. That can be welcome, but it also means people taking blood-pressure medicine may need closer review if lightheadedness starts.
-

Tirzepatide and Gallbladder Risk: Small but Real
Gallstones turn up in about 1 in 100 people on tirzepatide in the trials — barely above placebo — but inflamed gallbladders are three and a half times as common. Here is why, and the pain pattern that means call someone today.
-

Tirzepatide and Menopause: What the Evidence Says
Menopause does not appear to stop tirzepatide from working for weight management. The useful question is whether it fits the whole health picture, including sleep, muscle, bone and any hormone therapy already in use.
-

Tirzepatide Psoriasis Data Don’t Make It a Treatment
New 52-week data found better skin and joint outcomes when branded tirzepatide was added to Taltz in adults with psoriatic disease and obesity. That supports treating two linked conditions together—not using tirzepatide alone for psoriasis.
-

Tirzepatide 3 Month Supply: What You Get
Three months usually means a series of monthly dose packages, not one vial kept open for 90 days. The prescription, storage dates, and billing period each answer a different part of the question.
-

What Is Cagrilintide? The Amylin Half of CagriSema
Cagrilintide is an experimental copy of the appetite hormone amylin, and the other half of Novo Nordisk's CagriSema. It is not approved, it is not sold here, and a US decision is expected before the end of 2026.
-

Semaglutide and Tirzepatide Together? Usually No
Semaglutide and tirzepatide together are not a recommended combination. Both reach the same GLP-1 pathway; a switch should be planned as one treatment replacing the other, with timing and dose set by a prescriber.
-

GLP-1 Heart Failure Guidelines Changed in 2026
Europe's 2026 ESC guideline now says semaglutide or tirzepatide should be considered for a narrow group with symptomatic heart failure and obesity. It is an option for a cardiologist to weigh, not a direction to start either drug on your own.
-

How to Choose a Tirzepatide Provider: 7 Checks
Most of the difference between a careful service and a careless one shows up before a vial ever arrives — in who reads your history, who makes the medicine, and whether anyone answers afterwards.
-

Mounjaro vs Zepbound: Same Drug, Two Labels
Both pens hold tirzepatide and run the same dose ladder. What differs is the use printed on the carton — and that is what your insurer reads.
-

Semaglutide for Children: What STEP Young Means
Semaglutide for children ages 6 to 11 has encouraging new trial results, but the news has not changed who can receive Wegovy under its current label. The evidence is promising, early, and best read with a pediatrician.
-

What Is Semaglutide Used For? A Plain Guide
Semaglutide has different jobs depending on the brand: blood sugar control, heart or kidney risk reduction, long-term weight management, or certain liver disease. Here is the plain list before a first visit.
-

Best Tirzepatide Compounding Pharmacy Checklist
The best choice is a pharmacy you can verify: licensed, tied to a real prescription, clear about sterile preparation, and accountable for the vial after it leaves the building.
-

Tirzepatide Pills Don't Exist. Here's What Does
There is no oral tirzepatide, either as a brand product or a validated compounded pill. Real GLP-1 tablets contain semaglutide or orforglipron, which are different medicines.
-

Zepbound vs Wegovy: Two Drugs, Not Two Brands
They get compared like two versions of one medicine. They are not — different molecules, different makers, and different lists of what each one is cleared to treat.
Page 8 of 13 · 250 articles